AN2 Therapeutics Inc

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. “AN2's cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to bel.

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible violations of federal securities laws. Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.

Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by AN2 Therapeutics, Inc. (ANTX)

ANTX ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AN2 Therapeutics, Inc.

NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible violations of federal securities laws. Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.

AN2 Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ANTX

NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible violations of federal securities laws. Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.

AN2 Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ANTX

LOS ANGELES, CA / ACCESSWIRE / February 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or "the Company") (NASDAQ:ANTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AN2 Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

AN2 Therapeutics said on Monday it will pause further enrollment in a mid-to-late-stage study testing its experimental drug to treat a type of bacterial lung infection, citing potentially lower-than-expected efficacy.

AN2 Therapeutics to pause lung disease study enrollment

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the company's decision to voluntarily pause Phase 3 enrollment in the seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review. The double-blind, placebo-controlled trial has t.

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. Details of the event is as follows: Oppenheimer 34th Annual Healthcare Life Sciences Conference (virtual) Eric Easom, Co-Founder,.

AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

AN2 Therapeutics, Inc. (ANTX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2023. “We are incredibly proud of the significant milestones achieved recently and over the past quarter. In September, we initiated enrollment in the Phase 3 part of our pivotal Phase 2/3 clinical trial.

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics, Inc. (ANTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November. Stifel 2023 Healthcare Conference Eric Easom, Co-Founder, President and CEO will provide a corporate overview on Wednesday, November 15 at 3:00 p.m. ET. 6th Annual Ev.

AN2 Therapeutics to Present at Upcoming Investor Conferences

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received an exclusive license from the University of Georgia Research Foundation to advance the development of a boron-containing small molecule for Chagas disease. These boron-based molecules were originally discovered by researchers at Anacor.

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced two oral presentations and three poster presentations at the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts. AN2 Therapeutics is currently enrolling patients in the Phase 3 part of its p.

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis and malaria. Funding from the Gates Foundation will support the discovery of novel inhib.

AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has commenced the Phase 3 part of its Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory MAC lung disease after completing Phase 2 enrollment. The Phase 2/3 clinical trial is expected to support regulatory fil.

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease

Here is how AN2 Therapeutics, Inc. (ANTX) and Artivion (AORT) have performed compared to their sector so far this year.

Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?

AN2 Therapeutics, Inc. (ANTX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ANTX's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Should You Buy AN2 Therapeutics, Inc. (ANTX) After Golden Cross?

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of an underwritten offering of 7,777,778 shares of its common stock. The shares of common stock are being sold at a price of $9.00 per share, a premium from today's closing price. Investors who have agreed to purchase shares in the offering incl.

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended June 30, 2023. “We're pleased with the accelerated pace of enrollment in our pivotal Phase 2/3 study evaluating epetraborole for treatment-refractory MAC lung disease and believe we currently have sufficient patients i.

AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO, will present at the Jefferies Healthcare Conference. Details of the event are as follows: Jefferies Healthcare Conference, June 7-9, 2023 in New York, NY. Eric Easom, Co-Founder, President and CEO, will provid.

AN2 Therapeutics to Present at Jefferies Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2023. “In the first quarter we continued to advance our pivotal Phase 2/3 trial evaluating epetraborole for treatment-refractory MAC lung disease with a total of nearly 80 clinical sites active worldwide. We.

AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

AN2 is a developer of rare, infectious disease therapeutics. AN2 leverages its boron chemistry expertise and has a history of a successful sale to Pfizer.

News for AN2 Therapeutics Inc Stock (ANTX)